Payment overview · 2025
General Payments
$598.42
35 reported records · 12 companies
Healthcare provider profile · identity verified
Sara Sargent, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LANCASTER, OH · NPI 1083803779
Verified facts
What the public records show
CMS Open Payments records show Sara Sargent, CNP received $598.42 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $272.37 | 45.5% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.31 | 8.7% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.68 | 7.6% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $42.18 | 7.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.21 | 6.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.62 | 5.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.43 | 4.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.53 | 3.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.92 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.35 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.05 | 2.7% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.77 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $598.42 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $259.67 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $242.11 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.68 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $12.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 89 |
| Omeprazole | Omeprazole | 308 | 68 |
| Gabapentin | Gabapentin | 281 | 54 |
| Furosemide | Furosemide | 271 | 65 |
| Potassium Chloride | Potassium Chloride | 254 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 55 |
| Sertraline Hcl | Sertraline Hcl | 242 | 39 |
| Trazodone Hcl | Trazodone Hcl | 226 | 46 |
| Prednisone | Prednisone | 225 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 48 |
| Mirtazapine | Mirtazapine | 217 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 206 | 40 |
| Alprazolam | Alprazolam | 205 | 47 |
| Lorazepam | Lorazepam | 179 | 29 |
| Tramadol Hcl | Tramadol Hcl | 175 | 44 |
| Losartan Potassium | Losartan Potassium | 169 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 63 |
| Montelukast Sodium | Montelukast Sodium | 151 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 25 |
| Buspirone Hcl | Buspirone Hcl | 145 | 34 |
| Lisinopril | Lisinopril | 145 | 34 |
| Donepezil Hcl | Donepezil Hcl | 139 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 23 |
| Cephalexin | Cephalexin | 123 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 25 |
| Famotidine | Famotidine | 119 | 17 |
| Carvedilol | Carvedilol | 117 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 112 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 18 |
| Metformin Hcl | Metformin Hcl | 93 | 27 |
| Memantine Hcl | Memantine Hcl | 92 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 63 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 40 |
| Clonazepam | Clonazepam | 79 | 11 |
| Eliquis | Apixaban | 79 | 14 |
| Ozempic | Semaglutide | 79 | 15 |
| Pregabalin | Pregabalin | 79 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 78 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 12 |
| Fluconazole | Fluconazole | 71 | 35 |
| Single Use Swab | Alcohol Antiseptic Pads | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Bupropion Xl | Bupropion Hcl | 67 | 15 |
| Diazepam | Diazepam | 67 | 12 |
| Spironolactone | Spironolactone | 67 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 24 |
| Simvastatin | Simvastatin | 65 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 16 |
| Glimepiride | Glimepiride | 61 | 18 |
| Sucralfate | Sucralfate | 60 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 11 |
| Nystatin | Nystatin | 59 | 35 |
| Celecoxib | Celecoxib | 55 | 15 |
| Loperamide | Loperamide Hcl | 55 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 13 |
| Finasteride | Finasteride | 49 | suppressed |
| Azithromycin | Azithromycin | 45 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Meloxicam | Meloxicam | 44 | 15 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 25 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 18 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 18 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nystop | Nystatin | 17 | 12 |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Oxaprozin | Oxaprozin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $598.42 · 35 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ACCRUFER, CAPLYTA, Cologuard Collection Kit, Kerendia, Korlym, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XYOSTED, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error